USFDA completes inspection of Lupin’s Nagpur plant

New Delhi: Pharma major Lupin today said the US health regulator has completed inspection of its Nagpur facility without making any observations.

In a BSE filing, Lupin “announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations”.

Lupin said its Nagpur facility manufactures oral solid products.

Shares of Lupin were trading 2.09 per cent higher at Rs 767.50 on BSE.

  • Related Posts

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

    Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    STF busts fake meds racket spread across 6 states

    STF busts fake meds racket spread across 6 states